Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2021.
Financial Highlights
- Net Sales for the quarter at Rs 1292 crores.
- Net Profit for the quarter at Rs 169 crores.
- Net sales for H-1 FY21 at Rs 2618 crores.
- Net profit for H-1 FY21 at Rs 334 crores.
Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said “India Branded Formulation business has posted a strong growth rate for the second consecutive quarter. This is attributed to the consistent efforts to redefine our business strategy and customer relationships, leading to a strong operational performance, along with a market outperforming growth across all our key product segments and therapy areas.”
Operational Highlights
International Business
- US Generics at Rs 348 crores in the quarter and at Rs 716 Crores for H-1.
- Ex-US International Formulations at Rs 197 Crores in the quarter and at Rs 394 Crores for H-1.
- 5 ANDA approvals received during the quarter; 150 Cumulative ANDA approvals.
- 3 ANDA filings during the quarter; Cumulative ANDA filings at 214.
India Formulations Business
- India Formulations Business at Rs 509 crores in the quarter and at Rs 989 crores in the H-1.
- Acute & specialty segment grew faster than represented pharma market.
API Business
- API business at Rs 239 crores in the quarter and at Rs 519 crores for H-1.
- 3 DMF were filed in the quarter.
Summary of Total Revenue is as under:
(Rs in Crores)
| Particulars | Q2 FY22 | Q2 FY21 | % Change | H-1 FY22 | H-1 FY21 | % Change |
| Formulation | ||||||
| USA
Ex- US |
348
197 |
582
197 |
(40%)
0% |
716
394 |
1177
373 |
(39%)
6% |
| India | 509 | 415 | 23% | 989 | 721 | 37% |
| API | 239 | 263 | (9%) | 519 | 528 | (2%) |
| Total | 1292 | 1457 | (11%) | 2618 | 2798 | (6%) |
Summary of Profit is as under: (Rs in Crores)
| Particulars | Q2 FY22 | Q2 FY21 | % Change | H1 FY22 | H1 FY21 | % Change |
| EBITDA Pre R&D | 420 | 628 | (33%) | 827 | 1177 | (30%) |
| EBITDA Pre R&D % | 33% | 43% | 32% | 42% | ||
| EBITDA Post R&D | 268 | 455 | (41%) | 522 | 871 | (40%) |
| EBITDA Post R&D % | 21% | 31% | 20% | 31% | ||
| Profit Before Tax | 209 | 406 | (49%) | 408 | 775 | (47%) |
| Net Profit after Tax | 169 | 333 | (49%) | 334 | 635 | (47%) |
